000			01929 a2200541 4500
005			20250515073142.0
264		0	_c20080331
008			200803s 0 0 eng d
022			_a0920-9964
024	7		_a10.1016/j.schres.2007.04.035 _2doi
040			_aNLM _beng _cNLM
100	1		_aMullins, C Daniel
245	0	0	_aRisk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. _h[electronic resource]
260			_bSchizophrenia research _cJan 2008
300			_a8-15 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAntipsychotic Agents _xadverse effects
650	0	4	_aAripiprazole
650	0	4	_aDibenzothiazepines _xadverse effects
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPatient Readmission _xstatistics & numerical data
650	0	4	_aPiperazines _xadverse effects
650	0	4	_aProportional Hazards Models
650	0	4	_aQuetiapine Fumarate
650	0	4	_aQuinolones _xadverse effects
650	0	4	_aRandomized Controlled Trials as Topic _xstatistics & numerical data
650	0	4	_aRisk Factors
650	0	4	_aRisperidone _xadverse effects
650	0	4	_aSchizophrenia _xdiagnosis
650	0	4	_aSchizophrenia, Paranoid _xdiagnosis
650	0	4	_aSchizophrenic Psychology
650	0	4	_aSensitivity and Specificity
650	0	4	_aSubstance Withdrawal Syndrome _xepidemiology
650	0	4	_aSurvival Rate
650	0	4	_aThiazoles _xadverse effects
700	1		_aObeidat, Nour A
700	1		_aCuffel, Brian J
700	1		_aNaradzay, John
700	1		_aLoebel, Antony D
773	0		_tSchizophrenia research _gvol. 98 _gno. 1-3 _gp. 8-15
856	4	0	_uhttps://doi.org/10.1016/j.schres.2007.04.035 _zAvailable from publisher's website
999			_c17133586 _d17133586